about
Pulmonary delivery of an ultra-fine oxytocin dry powder formulation: potential for treatment of postpartum haemorrhage in developing countriesEffective pulmonary delivery of an aerosolized plasmid DNA vaccine via surface acoustic wave nebulization.Structural influence of cohesive mixtures of salbutamol sulphate and lactose on aerosolisation and de-agglomeration behaviour under dynamic conditions.Ongoing in vivo studies with cytoskeletal drugs in tau transgenic mice.Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration.New developments in dry powder pulmonary vaccine delivery.Safety, Tolerability and Pharmacokinetics of Single Doses of Oxytocin Administered via an Inhaled Route in Healthy Females: Randomized, Single-blind, Phase 1 StudyDisposition and safety of inhaled biodegradable nanomedicines: Opportunities and challenges.Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa.Spray-Dried Influenza Antigen with Trehalose and Leucine Produces an Aerosolizable Powder Vaccine Formulation that Induces Strong Systemic and Mucosal Immunity after Pulmonary Administration.Preclinical comparison of intravenous melphalan pharmacokinetics administered in formulations containing either (SBE)7 m-β-cyclodextrin or a co-solvent system.Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections.A simple and efficient high-performance liquid chromatographic assay for etomidate in plasma.Desbutylhalofantrine: evaluation of QT prolongation and other cardiovascular effects after intravenous administration in vivo.Evaluation of the impact of altered lipoprotein binding conditions on halofantrine induced QTc interval prolongation in an anaesthetized rabbit model.Influence of physicochemical properties on the patterns of association of a series of aliphatic esters of halofantrine with plasma lipoproteins.The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules.In vitro and in vivo evaluation of a sulfobutyl ether beta-cyclodextrin enabled etomidate formulation.PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin.Ontogeny of the adrenal gland in the spiny mouse, with particular reference to production of the steroids cortisol and dehydroepiandrosterone.Lipid digestion as a trigger for supersaturation: evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems.Miniature inhalation therapy platform using surface acoustic wave microfluidic atomization.Preliminary evaluation of polymer-based drug composite microparticle production by coacervate desolvation with supercritical carbon dioxide.A comparison of the lung clearance kinetics of Solid lipid nanoparticles and Liposomes by following the 3H-labelled structural lipids after pulmonary delivery in rats.Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent.Differences in the lipoprotein binding profile of halofantrine in fed and fasted human or beagle plasma are dictated by the respective masses of core apolar lipoprotein lipid.Comparative canine pharmacokinetics-pharmacodynamics of fospropofol disodium injection, propofol emulsion, and cyclodextrin-enabled propofol solution following bolus parenteral administration.Hemodynamic profile in rabbits of fospropofol disodium injection relative to propofol emulsion following rapid bolus injection.Evaluation of mean arterial blood pressure, heart rate, and sympathetic nerve activity in rabbits after administration of two formulations of etomidate.Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers.Stability Enhancing N-Terminal PEGylation of Oxytocin Exploiting Different Polymer Architectures and Conjugation Approaches.Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model.The Lymphatic System Plays a Major Role in the Intravenous and Subcutaneous Pharmacokinetics of Trastuzumab in RatsKnowledge, perception and practice towards oxytocin stability and quality: A qualitative study of stakeholders in three resource-limited countriesAssessing the operational feasibility and acceptability of an inhalable formulation of oxytocin for improving community-based prevention of postpartum haemorrhage in Myanmar: a qualitative inquiryQuality of oxytocin ampoules available in health care facilities in the Democratic Republic of Congo: an exploratory study in five provincesProbing a Potential In Vivo Drug–Excipient Interaction: Temporal Effects of a Modified β-Cyclodextrin on the Intravenous Pharmacokinetics of a Model High-Affinity Drug LigandInvestigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery: A design of experiment approach
P50
Q28537941-4B103AEB-44AE-4208-B6D4-0D2BA7AED1F5Q30437330-2C56F740-EC89-432F-B4CD-4982E66F4CFFQ33757211-1F4219F6-FC79-4D71-9281-1B665A732892Q36536227-A2A67122-D165-4F4B-AB8B-1FC8CA17C845Q37538748-BE6F0DB7-62D9-4D8C-871A-CFF1775C1059Q37713056-1963720D-6283-419B-A247-ADF657890B73Q37831512-C3A93A4E-5A58-4B5E-B4D1-563CE3B4A8C7Q38638310-CB8887A3-3A96-4EDE-9AE5-05D297196D56Q38795185-3701AE09-1075-4FD2-97B5-48822895AC62Q40697349-7BF53239-DB3F-487A-ADD8-29F74068F16CQ40698278-E0ED0EC0-69B3-4534-9206-F4550AA9209FQ42159867-5A19AD8E-F330-4097-B170-7F01A08A295FQ42877606-CB1D3AE6-5386-47F9-B2E5-BBA36695A3A0Q42930245-5E5AE092-85BE-4FF2-8B24-EE755B7CF21FQ43555765-67412CB2-E42F-4CBF-883C-7A0D36DE6DF4Q44327631-3785CC70-5304-4B30-9A85-A7BA17532ABBQ44773929-6E020E03-007A-4252-9F08-6E0499B06390Q44774564-909D23CE-4EC8-48C6-B5D6-474A40D29A48Q44931279-9DDD397B-AFB9-4318-9D10-2D0CA7E9FA85Q45045545-7B137464-BBC9-4FFF-BDC2-AA62EA2B8CB5Q45253881-65FB0CD1-3064-4BC1-9432-1F7E35B63ADCQ45735842-26910379-D532-48F9-97CD-B1342CC7336FQ45899316-B5E3B82A-56EF-455C-8A6A-979BB0D9F574Q45928155-DA924103-6782-4324-83D2-8A2EC2FB1687Q46898506-8639CCC9-1899-41EE-8103-E84DD3D86A2AQ47197520-516879BD-392E-4402-AA15-28158AEAEFC2Q47230465-7CF8C830-4F88-4DA7-A6CB-AD3C47BDCCCAQ47843954-BD9D867C-F48A-49B8-A4E0-AE79CE7970D6Q48162710-4553322F-83DF-4379-AD7D-485D65B6353DQ48167911-3B78C857-0246-4CC3-A033-3D7BF12D9E17Q48605155-3E2E21CD-469F-4AE9-A0E4-FC2263338192Q50528173-F7062CDE-1F6A-4C04-902F-B3F492CCEA15Q51639980-0E06EE65-54FA-4BEF-B74E-07AA5513D933Q53704512-9FF36C4B-874D-49CC-A767-DE0673639E94Q57240417-9686AE78-95A1-4FD2-8D4B-50C80430A9B3Q57945682-D05D1EDC-4AB1-4EEA-A015-1BAF34B90A43Q58565493-FED4E488-0062-4341-9683-42853FACD0E1Q58762185-136D2784-13C3-420D-9781-FF9942473DDFQ58866632-D89C9AB0-BF7A-414A-BF27-40AE3ACD0DC0Q61639927-78D4173B-1802-49D9-AF7F-61262197FD24
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Michelle P. McIntosh
@ast
Michelle P. McIntosh
@en
Michelle P. McIntosh
@es
Michelle P. McIntosh
@nl
Michelle P. McIntosh
@sl
type
label
Michelle P. McIntosh
@ast
Michelle P. McIntosh
@en
Michelle P. McIntosh
@es
Michelle P. McIntosh
@nl
Michelle P. McIntosh
@sl
prefLabel
Michelle P. McIntosh
@ast
Michelle P. McIntosh
@en
Michelle P. McIntosh
@es
Michelle P. McIntosh
@nl
Michelle P. McIntosh
@sl
P244
P106
P1153
7103029609
P21
P214
4209153775054861550003
P244
no2018123262
P31
P496
0000-0002-1605-7226
P734
P735
P7859
lccn-no2018123262